ERBB2 and breast cancer: A fourth study (BCIRG006) assigned patients with early-stage HER2 amplified breast cancer to receive either AC-T, AC-T+trastuzumab, or a new anthracycline-sparing, platinum-containing regimen: TCH (docetaxel, carboplatin, and trastuzumab)189.